April 8, 2021 11:03 AM EDT
News Briefing

Bio­gen ac­quires rights for po­ten­tial Actem­ra biosim­i­lar; Roy­al­ty Phar­ma buys lumasir­an roy­al­ty stream for up to $240M

Max Gelman

Senior Editor

Bio­gen has a new part­ner to help de­vel­op an ex­per­i­men­tal IL-6 biosim­i­lar.

The Cam­bridge, MA-based com­pa­ny an­nounced Thurs­day it has teamed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times